The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC).
T. Ciuleanu
No relevant relationships to disclose
V. Nikolic
No relevant relationships to disclose
E. Shmueli
No relevant relationships to disclose
D. Vrbanec
No relevant relationships to disclose
S. Plate
No relevant relationships to disclose
Z. M. Krmpotic
No relevant relationships to disclose
M. Dank
No relevant relationships to disclose
G. Purkalne
No relevant relationships to disclose
T. Brodowicz
No relevant relationships to disclose
C. Zielinski
Consultant or Advisory Role - Merck Serono; Roche